ACN vs AVGO

Accenture (ACN) exhibits mixed fundamental health, with a Piotroski F-Score of 4/9 indicating a borderline stable financial position, and no Altman Z-Score available to assess distress risk. The stock trades at a premium to its Graham Number ($116.86) and intrinsic value estimate ($84.7), suggesting valuation is driven by growth expectations rather than conservative safety. Despite strong profitability metrics—ROE of 25.02% and gross margin of 31.97%—earnings growth has turned negative (-1.60% YoY), and recent price performance reflects significant underperformance over 1Y (-39.2%) and 5Y (-20.8%). Analysts remain optimistic with a buy recommendation and a target price of $268.51, but insider activity is neutral, and technical trends are bearish.

Broadcom exhibits a dichotomy between elite operational performance and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health, the stock trades at a massive premium to its Graham Number ($44.08) and Intrinsic Value ($151.04). This valuation gap is partially justified by a very attractive PEG ratio (0.68) and strong forward P/E (19.65), suggesting high growth expectations. However, aggressive insider selling by the CEO and CFO, combined with a bearish technical trend, offsets the strong analyst 'strong_buy' consensus.